Psyomics Launches New Healthtech Platform to Transform Neurodiversity Assessment and Triage

UK-based healthtech company Psyomics, a Cambridge University biotech spinout, has launched a new digital platform designed to transform the way neurodiversity and mental health conditions are assessed, triaged and supported across behavioural health, child and adolescent services and neuropsychiatric pathways. Led by CEO Dr. Melinda Rees, Psyomics aims to bring clinical-grade assessment tools directly into digital workflows, helping healthcare systems deliver earlier, more accurate support to individuals who often wait months or years for specialist evaluation.

The launch coincides with Psyomics securing $5 million in pre-Series A funding, which will accelerate the company’s US market expansion, support clinical trials for a world-first bipolar blood biomarker and advance its pathway towards FDA medical device accreditation. With demand for neurodevelopmental assessments rising globally, the company says these investments will help bring its technology to health systems facing severe capacity constraints.

Founded by Professor Sabine Bahn, Laboratory Director at the Cambridge Centre for Neuropsychiatric Research, Psyomics brings more than six years of scientific research into a platform built to streamline the clinical journey for patients with complex mental health and neurodevelopmental needs. Having already supported more than 8,500 patients since late 2022, the company’s digital assessment technology is now being extended specifically to meet the rising demand for neurodiversity-focused care.

A Growing Crisis in Neurodiversity Assessments

Demand for autism, ADHD and neurodevelopmental assessments has surged across the UK in recent years. NHS waiting lists for child and adolescent mental health services (CAMHS) have reached unprecedented levels, with many families waiting more than a year for an initial appointment. A similar bottleneck now exists in the US, where 15.5 million adults are estimated to have ADHD or ASD and diagnoses have risen sharply over the past decade.

Government task forces have warned of a “timebomb” of untreated neurodevelopmental conditions, with evidence linking delayed assessment to heightened risks of suicide, substance abuse, incarceration and chronic unemployment.

Clinicians across both regions face mounting caseloads and time-consuming documentation requirements, leaving little room for structured, evidence-based triage. Psyomics says its new platform was built to address this system-wide strain. By capturing rich, structured patient-reported information before clinical appointments, the platform reduces triage and assessment time and ensures clinicians receive a comprehensive profile of each patient’s symptoms, functional impact and developmental history.

This approach aims to support earlier intervention, reduce misdiagnosis and direct individuals to the most appropriate pathway, whether that is autism assessment, ADHD evaluation, behavioural health support or specialist psychiatric care.

A Digital Platform Built on Clinical and Scientific Rigor

At the core of the Psyomics platform is a dynamic, adaptive assessment engine that mirrors the structured questioning of an experienced clinician. Rather than relying on single-screening tools or surface-level questionnaires, Psyomics uses branching logic that adjusts questions based on patient responses, enabling a deeper and more personalised picture of mental health.

The platform, now formally introduced as beseen for neurodiversity, supports the assessment and triage of 15+ mental health conditions, including autism spectrum condition, ADHD, anxiety disorders, depression, PTSD, bipolar spectrum symptoms, behavioural concerns and functional & developmental difficulties.

Developed through years of clinical research at Cambridge and informed by collaboration with more than 15 NHS providers, the platform is designed to complement rather than replace clinical judgement. Insights are synthesised into a structured clinical summary that accelerates diagnostic decisions, reduces administrative burden and improves overall care coordination.

Advanced algorithms analyse referral data to route patients to the right pathway faster, while EHR integration ensures real-time updates on patient status during long waiting periods. This prevents clinicians from working with outdated information, a common issue in overloaded healthcare systems. Early deployment data shows up to 30% reduction in clinical administrative time and adult platform for behavioural health reduced waiting times from 42 to 29 days, a 31% improvement.

Targeted Solutions for Behavioural Health and Neurodiverse Populations

Psyomics offers a suite of solutions tailored for different clinical environments:

• BeSeen in Behavioural Health: A digital intake and triage system equipping behavioural health teams with detailed structured assessments before appointments. This supports faster diagnosis and improves caseload prioritisation in community mental health settings.
• BeSeen for Child & Adolescent Services: Built for paediatric and youth pathways, helping schools, CAMHS teams, paediatric clinics and family services identify early signs of neurodevelopmental conditions and behavioural challenges.
• Bipolar Biomarker Initiative: Leveraging the company’s neuropsychiatric research roots, this programme focuses on developing biological and behavioural markers to improve early detection of bipolar spectrum disorders, one of the most misdiagnosed conditions in psychiatry.

Across all solutions, Psyomics emphasises clinician support rather than algorithmic decision-making, delivering comprehensive case summaries, flagged areas of concern and risk insights.

A Healthtech Company With Deep Cambridge Roots

The scientific foundation of Psyomics sets it apart from many new entrants in the mental health technology space. Professor Sabine Bahn, an internationally recognised psychiatrist, founded the company after decades of research into biomarkers, psychiatry and neurodevelopmental disorders. This academic lineage, combined with the leadership of Dr. Melinda Rees, an experienced clinical psychologist and mental health service leader gives Psyomics both scientific credibility and practical clinical insight.

The executive team also includes Chief Commercial Officer Rupert Hipwell and Chief Technology Officer Alex Nancekievill, who lead the company’s partnerships, platform roadmap and expansion strategy. Today, Psyomics platforms are available to six million people across the UK, underlining strong adoption across NHS-backed pathways.

Addressing an Urgent Global Need

Clinicians across the UK, Europe and the US report that mental health assessment workloads have become unsustainable. Neurodiversity referrals alone have increased sharply across primary care, schools and paediatric services. With long waiting lists and fragmented referral pathways, families often experience prolonged uncertainty and delayed care.

Psyomics argues that digital triage is now essential as a structured gateway that captures accurate information early in the care journey. By doing so, it reduces the time clinicians spend gathering histories and enables them to focus on higher-value diagnostic and therapeutic work.

As the company expands in Europe and accelerates its US rollout with new funding, Psyomics aims to redefine the clinical workflow for neurodevelopmental and mental health assessment.

A New Standard for Digital Mental Health Assessment

With increasing pressure on mental health services globally and a clear shift toward personalized, efficient care pathways, Psyomics is positioning its platform as a foundational layer for next-generation neurodiversity and mental health assessment.

As the company extends partnerships across the UK and moves into international markets, its mission remains consistent: to provide earlier, more accurate support, reduce clinical bottlenecks and bring scientific rigour into digital mental health workflows.

Psyomics stands out in a crowded mental health-tech landscape because it elevates the standard of care. Unlike many startups offering generic questionnaires or chatbot-led evaluations, Psyomics has anchored its platform in clinical research, NHS validation and measurable outcomes.

The introduction of a neurodiversity-focused system, along with its simultaneous push into the US, reflects a level of ambition and maturity rarely seen in early-stage healthtech. If Psyomics can maintain scientific integrity while scaling internationally, it could become one of the defining companies shaping the future of clinical triage and neurodevelopmental assessment.